Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guido Marcucci

Showing results (471-480 of 476) with videos related to

Pageof 48
Sort By:
You have reached the last page of results.This site can display upto 476 results.
Cancer Medicine|August 18, 2018
Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit)Celalettin Ustun, Elizabeth Morgan, Erica E M Moodie, et al.
Blood Advances|May 18, 2021
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)Se Young Han, Krzysztof Mrózek, Jenna Voutsinas, et al.
The Journal of Clinical Investigation|September 4, 2013
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cellsPaolo Neviani, Jason G Harb, Joshua J Oaks, et al.
Nature Communications|November 9, 2016
Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemiaZhaohui Gu, Michelle Churchman, Kathryn Roberts, et al.
Nature Genetics|November 8, 2016
Deregulation of DUX4 and ERG in acute lymphoblastic leukemiaJinghui Zhang, Kelly McCastlain, Hiroki Yoshihara, et al.
The New England Journal of Medicine|September 11, 2014
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemiaKathryn G Roberts, Yongjin Li, Debbie Payne-Turner, et al.
Pageof 48

Showing results (471-480 of 476) with videos related to

Sort By:
Pageof 48
You have reached the last page of results.This site can display upto 476 results.
Cancer Medicine|August 18, 2018
Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit)Celalettin Ustun, Elizabeth Morgan, Erica E M Moodie, et al.
Blood Advances|May 18, 2021
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)Se Young Han, Krzysztof Mrózek, Jenna Voutsinas, et al.
The Journal of Clinical Investigation|September 4, 2013
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cellsPaolo Neviani, Jason G Harb, Joshua J Oaks, et al.
Nature Communications|November 9, 2016
Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemiaZhaohui Gu, Michelle Churchman, Kathryn Roberts, et al.
Nature Genetics|November 8, 2016
Deregulation of DUX4 and ERG in acute lymphoblastic leukemiaJinghui Zhang, Kelly McCastlain, Hiroki Yoshihara, et al.
The New England Journal of Medicine|September 11, 2014
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemiaKathryn G Roberts, Yongjin Li, Debbie Payne-Turner, et al.
Pageof 48